Article | February 28, 2023

Top 5 Considerations For CAR-T Trials During A Macroeconomic Downturn

GettyImages-1181729539 car_t

In a macroeconomic downturn, the cost of staffing a clinical trial, procuring reagents, and stocking single-use supplies — among numerous other expenses — can range from inconvenient to disastrous. Trials examining CAR-T cell therapies, which require specialized expertise and materials, are among the hardest-hit.

However, economic downturns, while threatening and unwelcome, offer opportunities to improve operations through technology, training, and hiring. In some situations, organizations can benefit by claiming a manufacturing slot a failing project has vacated, advancing its own timeline.

It can be easy to instead react defensively. Life science company management can get caught up looking at the problems and challenges of tomorrow (e.g., an ongoing submission) without fully considering any given action’s effect on the organization’s entire portfolio of assets. Accordingly, five key strategies can help organizations planning or executing CAR-T cell therapy trials to not only endure macroeconomic hardship, but to emerge more efficient and well-prepared on the other side.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader